Background: Although upregulated expression of local IgD has been reported in patients with chronic rhinosinusitis (CRS), its function is unclear. Objective: We sought to explore the expression and function of soluble IgD in patients with CRS, particularly CRS with nasal polyps. Methods: IgD levels in sinonasal mucosa were analyzed by using RT-PCR and ELISA. Numbers and phenotypes of IgD 1 cells were studied by means of immunohistochemistry, immunofluorescence, and flow cytometry. HMC-1 cells, a human mast cell line, and mast cells purified from eosinophilic polyps were cultured alone or with naive B cells purified from peripheral blood. The antigen specificity of nasal IgD was investigated by using ELISA. Results: The mRNA expression of immunoglobulin heavy constant delta gene, numbers of IgD 1 cells, and protein levels of secretory IgD in sinonasal mucosa were increased in patients with CRS with or without nasal polyps compared with control subjects. Numbers of IgD 1 plasmablasts were increased in both eosinophilic and noneosinophilic polyps, whereas numbers of IgD 1 mast cells were only increased in eosinophilic polyps. Cross-linking IgD induced serum preincubated HMC-1 cells and polyp mast cells to produce B-cell activating factor, IL-21, IL-4, and IL-13 and to promote IgM, IgG, IgA, and IgE production from B cells. In eosinophilic polyps expression of those B cell-stimulating factors in mast cells and close contact between mast cells and B cells were found. Moreover, positive correlations of total IgD levels with total IgE levels and
IgD-activated mast cells induce IgE synthesis in B cells in nasal polyps
Chronic rhinosinusitis (CRS) is a highly prevalent chronic inflammatory disease of the sinonasal mucosa. 1 Clinically, it can be divided into 2 subgroups: chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). It is generally considered that CRSwNP is characterized by T H 2-biased eosinophilic inflammation with local IgE production, whereas CRSsNP is more neutrophilic and type 1/type 17 response dominant. [2] [3] [4] However, the immunopathologic features of CRS vary across different geographic areas and populations with distinct racial backgrounds, and about half of Asian patients with CRSwNP do not demonstrate eosinophilic inflammation. 4, 5 Current treatment approaches for CRS include medical treatments involving nonspecific suppression of inflammation and endoscopic sinus surgery. Nevertheless, a significant number of patients respond poorly to these treatments, reflecting our limited understanding of the pathogenesis of CRS.
Accumulating evidence has implicated involvement of local immunoglobulin, including IgE, IgG, IgA, and IgD, in the pathogenesis of CRS. [6] [7] [8] Compared with other immunoglobulins, IgD remains an enigmatic antibody class. 9, 10 IgD is expressed as a transmembrane or secretory molecule in a species-specific manner. 11, 12 Transmembrane IgD is one of the major antigen receptor isotypes on the surfaces of human mature naive B cells. 13, 14 After encountering antigen, mature B cells transcriptionally downregulate surface IgD, 15 thereafter undergo somatic hypermutation and class-switch recombination of DNA, and differentiate into antibody-secreting plasma cells and memory B cells. 13 In addition to switching from IgM to IgG, IgA, and IgE, some B cells switch to IgD. 16 Secreted IgD is released into blood, as well as being present in respiratory, salivary, lacrimal, and mammary secretions. 13 Recently, class-switch recombination to IgD and IgD 1 IgM 2 plasmablasts have been found in the upper airway mucosa. 14 Secreted IgD can afford protection to the respiratory mucosa by binding to pathogenic bacteria, such as Moraxella catarrhalis and Haemophilus influenzae, and their virulence factors. 14 In addition, secreted IgD participates in B-cell homeostasis and demonstrated enhanced accumulation of IgD 1 cells in both patients with CRSsNP and those with CRSwNP. 18 Nevertheless, more importantly, the specificity and function of IgD have not been explored in those studies.
In this study we studied the expression, specificity, and function of secreted IgD in patients with CRS, especially CRSwNP. We found upregulated mucosal soluble IgD production in both patients with CRSwNP and those with CRSsNP, with the greatest level in patients with eosinophilic CRSwNP. Numbers of IgD 1 mast cells and levels of specific IgD against dust mite antigens were increased, although only in patients with eosinophilic CRSwNP. IgD-activated mast cells induced IgE production from B cells, which potentially contributed to eosinophilic inflammation in patients with CRSwNP.
METHODS Patients
This study was approved by the Ethics Committee of Tongji Hospital and conducted with written informed consent from every patient. A total of 144 patients with CRSwNP, 32 patients with CRSsNP, and 109 control subjects were enrolled in this study. The diagnosis of CRS was made according to the European Position Paper on Rhinosinusitis and Nasal Polyps. 2 CRSwNP was defined as eosinophilic when the percentage of tissue eosinophils exceeded 10% of total infiltrating cells, as reported by our previous study. 5 This cutoff was calculated as twice the SD of the mean eosinophil percentage in control subjects. 5 Patients without a history of CRS undergoing nasal surgery for a variety of non-CRS indications were enrolled as control subjects. Polyp tissues from patients with CRSwNP, diseased sinus mucosal samples from patients with CRSsNP, and ethmoid sinus tissues or inferior turbinate tissues from control subjects were obtained during surgery. Because of the limited amount of tissue samples, not all samples were included in every study protocol. Patients' characteristics are summarized in Table E1 in this article's Online Repository at www.jacionline.org, and other additional information is provided in the Methods section in this article's Online Repository at www.jacionline.org.
RT-PCR
Quantitative RT-PCR was performed with specific primers (see Table E2 in this article's Online Repository at www.jacionline.org), as stated elsewhere. 14, 19 More information is provided in the Methods section in this article's Online Repository.
Immunohistochemistry and immunofluorescence
Immunohistochemistry and immunofluorescence staining were performed, as previously described. 5, 7, 19 The antibodies used are listed in Tables E3 and E4 in this article's Online Repository at www.jacionline.org. More information is provided in the Methods section in this article's Online Repository.
Mononuclear cell isolation
Sinonasal mucosal samples were dissociated mechanically. 20 Nasal mucosal mononuclear cells (NMCs) from dispersed tissue cells and PBMCs were isolated by means of density gradient centrifugation on Lymphoprep (AXIS-SHIELD PoC AS, Oslo, Norway), as previously described. 20 More information is provided in the Methods section in this article's Online Repository.
Flow cytometry
NMCs and PBMCs were stained with specific primary antibodies (see Table E5 in this article's Online Repository at www.jacionline.org) and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, Calif). More information is provided in the Methods section in this article's Online Repository.
Purification of mast cells and naive B cells
Nasal mast cells from eosinophilic polyps and naive B cells from peripheral blood were isolated from NMCs and PBMCs by means of immunomagnetic cell sorting, respectively. 20, 21 The representative results of purification of naive B and mast cells are shown in Fig E1 in 
Stimulation of mast cells
HMC-1 cells (ATCC, Manassas, Va), a human mast cell line, were preincubated with human sera from control subjects overnight. Serum incubated HMC-1 cells and isolated polyp mast cells were stimulated with mouse mAb against IgD or IgE.
14,22 After a 16-hour stimulation, supernatants were collected for cytokine measurement. 14, 20 More information is provided in the Methods section in this article's Online Repository.
Coculture of mast cells and naive B cells
Peripheral naive B cells were cultured with autologous polyp mast cells or serum preincubated HMC-1 cells, and cells were treated with mAbs against IgD or IgE. 14, 21 After an 8-day culture, culture supernatants were harvested for immunoglobulin analysis. 14, 20 More information is provided in the Methods section in this article's Online Repository.
Measurement of immunoglobulin and cytokine levels
Total and specific IgE levels were measured by using the ImmunoCAP system (Phadia, Uppsala, Sweden). 7, 19 Levels of other immunoglobulins and cytokines were measured by using commercially available ELISA kits or Bio-Plex suspension chip technology. 7, 14, 19 Lower detection limits for ELISA assays and Bio-Plex suspension chip technology were shown in Tables E6 and E7, Table E8 in this article's Online Repository at www.jacionline.org). More information is provided in the Methods section in this article's Online Repository.
Statistics
Statistical analysis was performed by using SPSS 18.0 software (SPSS, Chicago, Ill). Expression results are presented in dot plots. Symbols represent individual samples; horizontal bars represent medians, and error bars show interquartile ranges. When comparisons were made between groups, the Kruskal-Wallis H test was used to assess significant intergroup variability. The Mann-Whitney U 2-tailed test was used for between-group comparison. The Spearman rank test was used for correlations. Cell-culture data are expressed as means 6 SEMs and analyzed by using the paired Student t test. A P value of less than .05 was considered significant.
RESULTS

Increased levels of mucosal IgD in patients with CRS
We first detected the mRNA expression of gene immunoglobulin heavy constant delta (IGHD) in nasal tissues, which reflects local IgD synthesis, including the transmembrane and secretory type. Compared with control inferior turbinate or ethmoid sinus mucosal samples, mRNA expression of IGHD in diseased sinus mucosa was upregulated in patients with CRSsNP and in patients with CRSwNP of both the eosinophilic and noneosinophilic types (Fig 1, A) . The secretory type of IgD, as detected by means of ELISA, was found to be upregulated in the sinonasal mucosa in patients with all types of CRS (Fig 1, B) . The immunohistochemistry study revealed enhanced accumulation of IgD 1 cells in the lamina propria of sinonasal mucosa from patients with CRS (Fig 1, C and D) . In contrast, we did not find significant differences in serum IgD levels among different subject groups (see Fig E3 in this article's Online Repository at www.jacionline.org).
Among different types of CRS, eosinophilic CRSwNP demonstrated the highest levels of local IgD expression (Fig 1) . Therefore we next focused on the role of IgD in pathophysiology of patients with eosinophilic CRSwNP. Control inferior turbinate and control ethmoid sinus mucosal samples had comparable IgD expression (Fig 1) . Given the larger amount of samples generally obtained from inferior turbinates, we used inferior turbinate tissues as a control for immunofluorescence and flow cytometry study thereafter. 
CD19
1 B cells in lamina propria were increased in both eosinophilic and noneosinophilic polyps compared with control inferior turbinate tissues, with a further increase in eosinophilic polyps (Fig 2, A and B) . Importantly, most IgD (Fig 1, A) , protein levels of secretory IgD (Fig 1, B) , and numbers of IgD 1 cells (Fig 1, C (Fig 2, E) and noneosinophilic CRSwNP (Fig 2, F) . Eos CRSwNP, Eosinophilic CRSwNP; Non-Eos CRSwNP, noneosinophilic CRSwNP. *P < .05, **P < .01, and ***P < .001.
Using flow cytometry, we confirmed that most polyp IgD 1 CD19 1 B cells were IgM 2 (Fig 2, C) , and those IgD 
CD138
2 plasmablasts with intracellular IgD expression (see Fig E5 in this article's Online Repository at www.jacionline.org), which is consistent with the previous report. 17 We found that the frequencies of total IgD 1 cells, as well as IgD 1 IgM 2 B cells, in NMCs were increased in both eosinophilic and noneosinophilic polyps, with a more prominent increase in eosinophilic polyps (Fig 2, D) . IgD 1 plasmablasts accounted for about 46% and 70% of total IgD 1 cells in eosinophilic and noneosinophilic polyps, respectively. We further found that the frequencies of IgD 1 IgM 2 B cells positively correlated with the levels of secretory IgD in both eosinophilic (Fig 2, E) and noneosinophilic polyps (Fig 2, F) Fig E6, B) .
To validate our immunofluorescence staining and flow cytometric data, we analyzed IgD expression on polyps (see Fig E7, A, in this article's Online Repository at www.jacionline. org) and peripheral CD3 1 T cells (see Fig E7, B) . Consistent with the previous report, 14 we did not find IgD expression on CD3
1 T cells (see Fig E7) . Eos CRSwNP, Eosinophilic CRSwNP; Non-Eos CRSwNP, noneosinophilic CRSwNP. **P < .01 and ***P < .001.
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Increased numbers of mucosal IgD 1 mast cells in patients with eosinophilic CRSwNP
Increased accumulation and activation of mast cells have been reported for eosinophilic polyps. 19, 24 Our flow cytometric analysis indicated that in addition to B cells, there were other types of IgD 1 cells in polyps (Fig 2, C) . Therefore we investigated the presence of IgD-armed mast cells in sinonasal mucosa. We found that the lamina propria of polyps was infiltrated by IgD 1 tryptase-positive cells (Fig 3, A) . Numbers of IgD 1 mast cells were increased in eosinophilic polyps compared with noneosinophilic polyps and control tissues, as detected by using immunofluorescence staining (Fig 3,  B) . Consistently, flow cytometric analysis demonstrated increased frequencies of total mast cells and IgD 1 mast cells in NMCs in eosinophilic but not noneosinophilic polyps in comparison with control tissues (Fig 3, D) . About 56% of mast cells had surfacebound IgD, and mast cells accounted for about 40% of IgD 1 cells in eosinophilic polyps.
IgD-activated HMC-1 cells produce B cell-stimulating factors
IgD cross-linking induced production of B-cell activating factors from IgD-armed basophils.
14 Given the significant accumulation of IgD-armed mast cells and upregulated local production of IgE in eosinophilic polyps, 19 we explored whether IgD cross-linking is able to activate mast cells and therefore contribute to local IgE production in eosinophilic polyps. Because we were unable to get commercially available IgD protein for cell culture, we incubated HMC-1 cells, a human mast cell line, with human normal serum. After incubation, about 18% and 7% of HMC-1 cells had surface-bound IgD and IgE, respectively (see Fig 
IgD-activated polyp mast cells produce B cell-stimulating factors
We next studied the effect of IgD cross-linking on polyp mast cells. Previous studies showed that mast cells in eosinophilic polyps also had surface-bound IgE. 19 Similar to the findings in IgD cross-linking activates polyp mast cells to produce B cell-stimulating factor, inflammatory cytokines, and chemokines. Mast cells purified from eosinophilic polyps were treated with anti-IgD, anti-IgE, or control mouse mAb for 16 hours, and levels of mediators in culture supernatants were measured (n 5 6). *P < .05, **P < .01, and ***P < .001.
HMC-1 cells, we found that both IgD and IgE cross-linking induced production of B cell-stimulating factors, proinflammatory cytokines, and chemokines from mast cells purified from eosinophilic polyps (Fig 4) . Again, because the proportions of IgD 1 and IgE 1 mast cells in total purified polyp mast cells were different, we did not compare the efficiency of IgE and IgD cross-linking. Differing from IgE, IgD cross-linking did not induce mast cell degranulation (data not shown), which is consistent with the finding of basophils.
14 Furthermore, we found that mast cells in eosinophilic polyps had expression of BAFF, IL-4, IL-5, IL-13, IL-10, IL-21, TGF-b1, IL-6, TNF-a, IL-1b, IL-8, and CXCL10 in vivo by using immunofluorescence staining (Fig 5) .
IgD-activated mast cells induce immunoglobulin production from B cells
Given the capacity of releasing B cell-stimulating factors by IgD-activated mast cells, we investigated whether IgD-activated mast cells were able to regulate B-cell antibody production. We found that IgD and IgE cross-linking upregulated the capacity of serum-incubated HMC-1 cells (see Fig E10 in this article' s Online Repository at www.jacionline.org) and polyp mast cells (Fig 6) to induce production of nonswitched IgM, as well as isotype class-switched immunoglobulins, including IgG 1 , IgG 3 , IgG 4 , IgA, and IgE, from B cells. We did not detect IgE production in the condition with anti-IgE treatment and IgG 2 production in all conditions because of the possible interference caused by experimental antibodies.
Interestingly, in polyp tissues we observed close contact between mast cells and B cells, which provided structure basis for the regulation of B cells by mast cells in vivo (Fig 7, A) . Consistent with our previous studies, 19, 20 we demonstrated increased local total IgE levels, but not serum total IgE levels, in patients with eosinophilic CRSwNP compared with those with noneosinophilic CRSwNP and control subjects (see Fig E11, A and B, in this article's Online Repository at www.jacionline.org). Moreover, there was no correlation between total IgE levels in tissues and those in sera in patients with eosinophilic CRSwNP (see Fig E11, C) , suggesting local production of IgE in eosinophilic polyps. In addition, we found significant correlations of total IgD levels with total IgE levels and eosinophil numbers in eosinophilic polyps (Fig 7, B) . Furthermore, we revealed significant associations between IgD 1 mast cells and total IgE levels and eosinophilia in patients with eosinophilic polyps (Fig 7, C) .
Polyp IgD recognizes aeroallergens and bacterial products
Chen et al 14 previously reported that IgD bound to the gram-negative bacteria M catarrhalis and H influenzae and J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 5 reacted to LPS and capsular polysaccharide.
14 Our previous study indicated that aeroallergens, particularly house dust mites, can induce local IgE production in patients with eosinophilic polyps. 7, 19, 20 Therefore we tested whether nasal mucosal IgD had antigen specificity against LPS and house dust mites, as determined by using a capture ELISA. We found that levels of LPS-specific IgD were upregulated in both patients with eosinophilic and those with noneosinophilic polyps, whereas the levels of Der f 1-and Der p 1-binding IgD were only increased in patients with eosinophilic polyps, but not noneosinophilic polyps, compared with control tissues (Fig 8) . Consistent with previous reports, 19 we found that levels of Dermatophagoides pteronyssinus-and Dermatophagoides farinae-specific IgE in polyp tissues, but not those in serum, were upregulated in patients with eosinophilic CRSwNP compared with patients with noneosinophilic CRSwNP and control subjects (see Fig E12, A-D, in this article's Online Repository at www.jacionline.org). Again, no correlation between local and serum specific IgE against house dust mites was found (see Fig E12, E and F) , further supporting local IgE production independent of systemic atopy in patients with eosinophilic CRSwNP. 8, 19, 22 In addition, we did not find a significant association between local Der p 1-specific IgD and D pteronyssinus-specific IgE or between local Der f 1-specific IgD and D farinae-specific IgE in patients with eosinophilic polyps (see Fig E12, G and H) .
DISCUSSION
The functional relevance of IgD in human diseases is poorly studied. In this study we showed that the numbers of IgD 
IgM
2 plasmablasts and levels of secretory IgD were increased locally, but not systemically, in both patients with CRSsNP and those with CRSwNP, indicating a localized IgD response in patients with CRS. Upregulation of local IgD production in patients with CRSsNP has been reported previously. 17, 18 Min et al 17 found that local soluble IgD levels were greater in those with preoperative antibiotic use or pathogenic bacteria presence, suggesting a potential involvement of IgD in immune response to bacterial infection in patients with CRSsNP. However, regarding local IgD production in patients with CRSwNP, inconsistent results have been reported. 17, 18 In this study, using several complimentary techniques, we demonstrated increased production of secretory IgD in Chinese patients with patients with CRSwNP. Interestingly, patients with eosinophilic CRSwNP demonstrated the highest levels of local IgD. These findings drove us to explore the role of soluble IgD in the pathogenesis of eosinophilic CRSwNP.
In addition to IgD 25 Cross-linking IgE bound to mast cells by corresponding antigens can lead to mast cell activation, which correlates with eosinophilia in nasal polyps. 19, 24 Nevertheless, the regulatory effect of IgD on mast cells is unknown. In this study, for the first time, we found that IgD cross-linking activated IgD-armed mast cells to release B cell2stimulating factors, which are crucial for the activation, proliferation, and class-switch recombination of B-cell DNA. These findings suggest a ''B cell2licensing'' function of mast cells with cross-linked IgD.
We further provided several additional lines of novel evidence for the regulatory function of IgD-activated mast cells on B-cell antibody production, especially IgE, in patients with Second, we found that IgD-activated mast cells isolated from eosinophilic polyps not only induced IgM, IgA, and IgG but also IgE production from B cells. Although we did not perform blocking experiments, the B cell-licensing function of IgDactivated mast cells was likely dependent on self-secreted BAFF and cytokines important for immunoglobulin class-switching, such as IL-21, IL-4, and IL-13. A proliferation-inducing ligand and CD40 ligand also play an important role in B-cell antibody production. 26 In this study we did not find robust changes of these molecules on HMC-1 cells after IgD cross-linking (data not shown); however, we could not preclude the involvement of these molecules in mast cell and B-cell interaction. Local IgA and IgG were reported to be upregulated in both patients with eosinophilic and those with noneosinophilic CRSwNP; however, local IgE levels were only found to be increased in patients with eosinophilic CRSwNP. 7, 20 Upregulation of local IgE irrespective of the presence of atopy and the presence of the markers of class-switch recombination to IgE, including ε germline gene transcript and ε circle transcripts in nasal polyps, strongly suggest local IgE production in nasal polyps. 8, 22, 27, 28 In this study the increase in total and specific IgE levels in polyps, but not in serum, and the lack of association between serum and polyp IgE levels in patients with eosinophilic CRSwNP confirmed a localized IgE production. Local IgE levels are associated with tissue eosinophilia, asthma comorbidity, and disease relapse after surgery in patients with CRSwNP. 8, 29, 30 Therefore the regulation of IgE production by IgD-armed mast cells is of particular importance for the pathogenesis of eosinophilic CRSwNP.
Third, interestingly, we found close contacts between mast cells and B cells in patients with eosinophilic polyps, providing a structural basis for interaction between B cells and mast cells in vivo.
Fourth, the positive associations of IgD and IgD 1 mast cells with IgE and eosinophilia in eosinophilic polyps further support the regulatory function of IgD on local IgE production and subsequent eosinophilic inflammation in patients with CRSwNP. In addition to secreting B cell-stimulating factors, we found that IgD-activated mast cells simultaneously produced inflammatory cytokines and chemokines, underscoring an inflammatory role of IgD beyond regulating B cells in patients with CRSwNP.
The specificity of nasal IgD has not been studied previously. Soluble IgD can enhance immune protection against local pathogens and commensal bacteria. 13, 14 Although there is not a definitive conclusion regarding the role of bacteria in CRS pathogenesis, a number of studies show that the microbiome of the nasal cavity differs significantly between patients with CRS and control subjects. 31, 32 Multiple microbial products, including LPS, are major triggers of inflammation. 33, 34 In the present study we found that IgD with binding activity to LPS was upregulated in both patients with eosinophilic and those with noneosinophilic CRSwNP, indicating that IgD can contribute to the immunity to bacterial infection not only in patients with CRSsNP, as previously suggested, 17 but also in patients with CRSwNP. Our pervious study indicated that polyp IgE can be induced by house dust mites, the most common aeroallergens in our area. 7 Serum total IgD and specific IgD levels against pollens have been reported to be upregulated in atopic patients. 23, 35 In this study we discovered an upregulation of specific IgD against Der p 1 and Der f 1 in eosinophilic, but not noneosinophilic, polyps, suggesting that in addition to IgE response, a localized IgD response to common aeroallergens was elicited during the development of eosinophilic CRSwNP. Nevertheless, more investigations are required to understand the relationship between soluble IgD production and allergen sensitization and bacterial infection in sinonasal mucosa. In the present study we could not directly demonstrate the effect of house dust mites in IgD-mediated response in eosinophilic polyps because of our technique limitations; however, it might be speculated that house dust mites cross-link IgD and activate mast cells in patients with eosinophilic CRSwNP. In this study we did not find an association between dust mite-specific IgE and IgD levels, indicating that IgD-activated mast cells more likely induce polyclonal B-cell activation through B cell-stimulating factors. Obviously, the complex interregulation of different immunoglobulins in patients with CRSwNP is an interesting topic for future investigations.
In conclusion, in this study we demonstrated an enhanced localized IgD response in both patients with CRSsNP and those with CRSwNP potentially induced by bacteria or aeroallergens. IgD-activated mast cells can facilitate local IgE production and exaggerate eosinophilic inflammation in patients with CRSwNP (see Fig E13 in this article' s Online Repository at www.jacionline. 450 and normalized to total protein levels of tissue homogenates. Eos CRSwNP, Eosinophilic CRSwNP; Non-Eos CRSwNP, noneosinophilic CRSwNP. *P < .05, **P < .01, and ***P < .001. org). Blocking IgD represents a potential novel therapeutic strategy to alleviate local IgE production and eosinophilic inflammation in patients with CRSwNP. Nevertheless, IgD likely has different pathologic roles in patients with CRSsNP and those with noneosinophilic CRSwNP, which deserves further studies.
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Clinical implications: Therapeutic strategies that target IgDmediated mast cell activation might be helpful to suppress local IgE production and eosinophilic inflammation in patients with CRSwNP.
METHODS Patients
This study was approved by the Ethics Committee of Tongji Hospital of Huazhong University of Science and Technology and was conducted with written informed consent from every patient. A total of 75 patients with eosinophilic CRSwNP, 69 patients with noneosinophilic CRSwNP, 32 patients with CRSsNP, and 109 control subjects were included in this study. The diagnosis of CRS was made according to the current European Position Paper on Rhinosinusitis and Nasal Polyps.
E1 CRSwNP was defined as eosinophilic when the percentage of tissue eosinophils exceeded 10% of total infiltrating cells, as reported in our previous study. E2 Patients without a history of CRS and undergoing nasal surgery for a variety of non-CRS indications (eg, septoplasty, skull base tumor, obstructive sleep apnea, and facial fracture repairs) were enrolled as control subjects. Atopic status was evaluated by using the skin prick test to a standard panel of aeroallergens common in our region and/or ImmunoCAP (Phadia, Uppsala, Sweden) to detect IgE antibodies against common inhalant allergens. E3 The diagnosis of asthma was made based on Global Initiative for Asthma guidelines. E4 Oral glucocorticoids and intranasal steroid sprays were discontinued at least 3 months and 1 month before surgery, respectively. None had received antileukotrienes or immunotherapy.
Subjects who had fungal sinusitis, cystic fibrosis, vasculitis, antrochoanal polyps, primary ciliary dyskinesia, gastroesophageal reflux disease or an acute upper respiratory tract infection within 1 month of entering the study were excluded from the study. None of the patients had a history of aspirin sensitivity. Polyp tissues from patients with CRSwNP, diseased sinus mucosal samples from patients with CRSsNP, and ethmoid sinus tissues or inferior turbinate mucosal tissues from control subjects were obtained during surgery. Because of the limited amount of tissue samples, not all samples were included in every study protocol. Demographic characteristics of patients are summarized in Table E1 .
Histology study
Paraffin-embedded sections (4 mm) of human sinonasal mucosa were stained with hematoxylin and eosin to determine the general pathologic features of tissues. Eosinophils and total inflammatory cells per high-powered field were evaluated. E2 RT-PCR analysis of IGHD As mentioned elsewhere, E2,E5 total RNA from tissue was extracted by using TRIzol (Invitrogen Life Technologies, Carlsbad, Calif) and treated with DNase (TaKaRa Biotechnology, Dalian, China) to avoid interference of genomic DNA. Then RNA was reverse transcribed to cDNA by using the Prime Script RT Reagent Lit (TaKaRa Biotechnology). Real-time PCR of IGHD was performed with the LightCycler system (Roche Diagnostics, Mannheim, Germany) with the SYBR Premix Ex Taq Kit (TaKaRa Biotechnology), with specific primers listed in Table E2. E2,E5 The specificity of primers for analysis of IGHD was confirmed by using the sequencing PCR product. cDNA equivalent to 50 ng of total RNA was used, and real-time PCR was performed on StepOnePlus (Applied Biosystems, Foster City, Calif). Amplification was as follows: 958C for 2 minutes, followed by 40 cycles of 958C for 10 seconds, specific annealing temperature for 10 seconds, and 728C for 15 seconds. After PCR, a melting curve was constructed by increasing the temperature from 658C to 958C, with a temperature transition rate of 0.18C/s. Relative gene expression was calculated by using the 2 2DDCT method.
E2,E5 An inferior turbinate sample from a control subject was used as a calibrator. b-Glucuronidase (GUSB) was used as a housekeeping gene for normalization of gene expression. No template sample was used as a negative control.
Immunohistochemistry and immunofluorescence
Paraffin-embedded sections (4 mm) were deparaffinized and rehydrated and then subjected to heat-induced antigen retrieval by using Target Retrieval Solution (Dako, Carpinteria, Calif). The 3% hydrogen peroxidase was used to inhibit endogenous peroxidase, and 5% BSA was used to block nonspecific binding. For immunohistochemistry, sections were stained with a specific primary antibody to IgD at a proper dilution (Table E3) , and the streptavidin-biotin-peroxidase complex detection method was used (Boster Biotechnology, Wuhan, China). Color development was achieved with 39, 39-diaminobenzidine. E2 For immunofluorescence staining, tissue sections were incubated with specific primary antibodies at proper dilutions (Table E3 ) overnight at 48C. After washing, sections were incubated with fluorescence-labeled secondary antibodies (Table E4) for 1 hour at room temperature. If necessary, sections were stained with 49-6-diamidino-2-phenylindole dihydrochloride at room temperature for 5 minutes. Speciesand subtype-matched antibodies were used as controls. Human tonsillar tissues were used as positive controls for IgD staining.
NMC and PBMC isolation
Sinonasal mucosa samples were dissociated mechanically, as previously stated. E6 The resulting cell suspensions were filtered 2 times through the mesh of a 40-mm cell strainer (BD Biosciences, San Jose, Calif). NMCs were isolated from dispersed tissue cells by means of density gradient centrifugation on Lymphoprep, as previously described. E6 PBMCs were also isolated by means of density gradient centrifugation on Lymphoprep.
E6
Flow cytometry
Isolated NMCs and PBMCs were first stained with the Fixable Viability Stain 700 (BD Biosciences) as a live/dead discriminator. E7 Cells were stained with appropriate combinations of antibodies to various surface antigens at 48C for 30 minutes.
E8,E9 Species-and subtype-matched antibodies were used as controls. For intracellular staining of IgD or tryptase, after surface staining, cells were fixed and permeabilized with the BD Cytofix/Cytoperm Kit (BD Biosciences). Cells were then stained with mouse mAb against human IgD or rabbit polyclonal antibody against tryptase for 30 minutes at 48C. If necessary, cells were incubated with secondary antibodies for 30 minutes at 48C. The detailed information of primary and secondary antibodies used is listed in Table E5 . Stained cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson). All gates and quadrants were drawn to result in 1% or less of total positive cells in the sample stained with control antibodies. Data were analyzed with FlowJo software (TreeStar, Ashland, Ore).
Purification of mast cells and naive B cells
Peripheral naive B cells and polyp mast cells were isolated from PBMCs and NMCs by means of immunomagnetic cell sorting, respectively. NMCs and PBMCs were obtained, as mentioned above. B cells were isolated from the low-density fraction of PBMCs, and naive CD19
1 IgD 1 B cells were isolated by means of depletion of nonnaive B cells through use of the Na€ ıve B Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's protocol. E6 Purity of CD19
was greater than 98%. The viability of purified peripheral naive B cells was greater than 97%. Nasal mast cells were purified from NMCs from eosinophilic polyp tissues through removal of monocytes by means of plastic adherence at 378C for 90 minutes and removal of CD3 1 cells (Miltenyi Biotec) and positive selection of CD117 1 (c-kit 1 ; Miltenyi Biotec) cells by using magnetically activated cell sorting, as previously described. E9,E10 The purity of purified nasal mast cells was greater than 98%, and the viability was greater than 95%. Representative results of purification of naive B cells and nasal mast cells are shown in Fig E1. Stimulation of mast cell line and polyp mast cells HMC-1 cells (ATCC), a human mast cell line, were cultured in RPMI 1640 medium (Gibco, Thermo Fisher Scientific, Waltham, Mass) with 10% (vol/vol) FBS (Gibco) and 1% (vol/vol) penicillin/streptomycin (Guge Biotechnology, Wuhan, China) in a 5% CO 2 -humidified atmosphere at 378C. Before stimulation, HMC-1 cells (1 3 10 7 cells) were preincubated with human serum (15 mL) from control subjects for 16 hours. After incubation, about 18% and 7% of HMC-1 cells had surface-bound IgD and IgE, respectively (Fig E8) . Serum preincubated HMC-1 cells were seeded onto 12-well plates at a density of 4 3 10 5 cells/well, and polyp mast cells were cultured at a density of 5 3 10 4 cells/well in U-bottom 96-well plates in RPMI 1640 medium (Gibco) supplemented with 10% (vol/vol) BSA (Gibco) and 1% (vol/vol) penicillin/streptomycin (Guge Biotechnology). Cultured HMC-1 cells and polyp mast cells were stimulated with mouse mAb against IgD (25 mg/mL; IgG 2a ; IA6-2; BD Biosciences), with mouse mAb against IgE (2 mg/mL; IgG 2a ; G7-18; BD Biosciences) as a positive control and control mouse mAb with the same isotype and irrelevant binding activity (25 mg/mL; IgG 2a ; sc-3878; Santa Cruz Biotechnology, Dallas, Tex) as a negative control.
E8,E9 After 16 hours of stimulation, culture supernatants were collected for cytokine detection.
Coculture of mast cells and naive B cells
Peripheral naive B cells were cultured alone or with autologous polyp mast cells (5 3 10 4 cells/well) or human serum preincubated HMC-1 cells (4 3 10 5 cells/well; 1:1 ratio) in RPMI 1640 medium (Gibco) with 1% (vol/vol) penicillin/streptomycin (Guge Biotechnology), 10% heat-inactivated FBS (HyClone, Thermo Scientific, Beijing, China), BAFF (500 ng/mL; BD Biosciences), and staphylococcal enterotoxin B (1 mg/mL; Millipore, Merck KGaA, Darmstadt, Germany) for 8 days in 96-well plates in a 5% CO 2 -humidified atmosphere at 378C.
E6,E8,E9 Mast cells were stimulated with mAb against IgD or IgE, as mentioned above. Culture supernatants were harvested for immunoglobulin analysis.
Measurement of immunoglobulins, cytokines, and chemokines
Tissue homogenates were generated, as previously described. E5 Briefly, every 0.1 g of tissue was added by 1 mL of 0.9% sodium chloride solution containing protease inhibitor cocktail (Guge Biotechnology). Tissues were then homogenized on ice. Tissue homogenates were generated, and human serum was centrifuged at 3000 rpm for 10 minutes at 48C. Supernatants were harvested and stored at 2808C for further analysis. Protein levels of IgD in tissue homogenates and serum, various cytokines in supernatants of HMC-1 cell culture, and TGF-b1 in supernatants of nasal mast cell culture were detected by using commercially available ELISA kits.
E6,E8 Lower detection limits for ELISA assays were shown in Table E6 . Cytokines, except TGF-b1, in supernatants of nasal mast cell culture and IgG 1 , IgG 3 , IgG 4 , IgM, and IgA in culture supernatants were measured by using Bio-Plex suspension chip technology (R&D systems, Minneapolis, Minn). E6,E8 Lower detection limits for Bio-Plex suspension chip technology were shown in Table E7 . Total and specific IgE levels in tissue homogenates, sera, and cell-culture supernatants were detected by using the ImmunoCAP system (Phadia, Uppsala, Sweden), and the lower detection level is 0.1 kU/L. E5 In culture supernatants IgG 2 levels in all conditions and IgE levels in the condition with anti-IgE antibody treatment were unable to be detected because of the possible cross-reactivity caused by experimental antibodies.
Measurement of antigen-specific IgD
A capture ELISA was developed to measure antigen-specific IgD. E11 Briefly, polystyrene microtiter plates were coated with 100 mL/well affinity-purified goat anti-human IgD antibody (Alpha Diagnostic International, San Antonio, Tex) or goat IgG isotype control (Alpha Diagnostic International) at a concentration of 10 mg/mL in 0.05 mol/L coating buffer at room temperature for 1 hour. After washing 5 times with washing buffer, plates were blocked with 200 mL/well blocking buffer overnight. After removing the blocking buffer and washing 5 times with washing buffer, 100 mL/well of tissue homogenates or PBS (negative control) was added and incubated for 2 hours. After washing, 100 mL/well of biotinconjugated Der p 1 (10 mg/mL), biotin-conjugated Der f 1 (10 mg/mL), biotin-conjugated LPS (10 mg/mL; InvivoGen, San Diego, Calif), 1% BSA (negative control), or HRP-conjugated goat anti-human IgD antibody (1 mg/mL; positive control) were added and incubated for another 2 hours. After that, 100 mL of streptavidin-HRP was added and incubated for 1 hour. Plates were subsequently incubated with 100 mL/well of tetramethylbenzidine substrate buffer for 30 minutes. OD 450 was determined by using an automated microtiter plate reader (Thermo Fisher Scientific). Because there are no standards available for antigen-specific IgD, results are presented as OD 450 values and normalized to total protein levels of tissue homogenates. Der p 1 (Prospec, East Brunswick, NJ) and Der f 1 (Prospec) were conjugated with biotin by using a Lightning-Link Rapid Biotin Conjugation Kit (Innova Biosciences, Cambridge, United Kingdom). E12 HRP-conjugated goat anti-human IgA, IgM, IgG, and IgE antibody at 1 mg/mL were used as cross-reaction controls. No cross-reaction was found (Fig E2) . The polystyrene microtiter plates, buffers, and all goat anti-human immunoglobulin antibodies were obtained from Bethyl Laboratories (Montgomery, Tex).
Antigen specificity of the assay was first examined with an inhibition test by using the same antigens without biotin conjugation. E12 Briefly, after incubating with tissue homogenates (100 mL/well) for 1 hour at room temperature, the plates were incubated with corresponding Der p 1 (Prospec), Der f 1 (Prospec), and LPS (InvivoGen) without biotin conjugation at a concentration of 10 mg/mL, 100 mg/mL, 1 mg/mL, or diluting buffer. As to nonspecific inhibition of antigen-specific IgD binding to corresponding allergen, LPS (1 mg/mL; InvivoGen) was used to inhibit antigen-specific IgD binding to Der f 1 and Der p 1. Nonspecific inhibition tests for antigen-specific IgD binding to LPS were carried out in the same manner by using Der p 1 (1 mg/mL; Prospec). Inhibition tests confirmed antigen specificity of developed ELISA, and results are shown in Table E8 . 
